greeksoup/ stock research
Stock research / United States / TEVA / FY2007

Teva Pharmaceutical Industries (TEVA) FY2007 results: revenue $9.4 billion

Teva Pharmaceutical Industries Ltd. (TEVA) reported revenue of $9.4 billion for fiscal 2007, the year ended 31 December 2007. Net income was $1.9 billion, and diluted earnings per share $2.36. The figures are the company's own, from the 20-F it filed with the SEC on 22 February 2010.

Revenue
$9.4 billion
FY2007FY2007
Operating margin
25.5%
FY2007FY2007
Net income
$1.9 billion
FY2007FY2007
Diluted EPS
$2.36
FY2007FY2007

this yearthe year beforeHover a bar for its figure.

The year in brief

Income statement (profit and loss)

$ millionFY2007Last 8 years
Revenue9,408
Cost of revenue4,531
Gross profit4,877
Gross margin51.8%
Research and development581
Operating income2,395
Operating margin25.5%
Pre-tax income2,304
Income tax386
Effective tax rate16.8%
Net income1,914
Net margin20.3%
Diluted EPS$2.36
$ million except per share.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow

$ millionFY2007Last 8 years
Operating cash flow1,813
Capital expenditure542
Free cash flow1,271
Free cash flow margin13.5%
Cash from investing-1,353
Cash from financing-362
Depreciation and amortisation499
Share-based compensation67.0
Buybacks152
Dividends paid299
Diluted shares, weighted830m

Balance sheet

$ millionFY2007Last 8 years
Shareholders' equity13,864
Cash and equivalents1,488

20-F for the year ended 31 December 2007, filed 22 February 2010: the filing.